Startup Japanese Biotechs License Kyoto U.’s iPS Cell Process
This article was originally published in PharmAsia News
Executive Summary
A pair of Japanese startup biotech firms, Reprocell and Takara Bio, have signed licensing agreements with Kyoto University to use its patented production process for induced pluripotent stem cells. The agreements are the school's first for the iPS cells. Reprocell intends to screen for side effects of drug candidates by using the cells and test compounds on cultivated heart muscle cells. Takara Bio has begun selling a reagent used in cultivating iPS cells using a different method, but it plans to expand its reach with the Kyoto cells. (Click here for more - a subscription may be required
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.